CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease research. They are a global company with facilities in the United States, Europe, and Asia.
CrownBio develops world-leading preclinical efficacy models and provides in vitro, in vivo, ex vivo, and in silico services. Their premier translational platforms help clients accelerate their new drug development programs.
As a comprehensive solution provider, CrownBio provides robust and scientifically sound end-to-end solutions for preclinical drug development. Their proprietary oncology platforms HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™, and HuSignature™ enable the rapid translation of lead compounds into successful clinical candidates, by revealing the best clinical possibilities. From large-scale in vitro and in vivo efficacy studies of drug candidates, to running surrogate trials in tandem with human clinical trials, CrownBio's well-characterized translational platforms deliver comprehensive and catered solutions for biopharmaceutical companies.
By providing the data needed to inform and accelerate oncology, inflammation, and cardiovascular and metabolic therapeutic development, CrownBio helps their clients make smarter decisions about their drug candidates.
With more experience than anyone in the industry, CrownBio's global resources truly help clients answer the most challenging questions about human biology.